ArticleNeurology and therapy2025

Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy: A 12‑Month Interim Analysis of a Postmarketing Surveillance Study.

Kayoko Saito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.